Quick Answer
Zentalis Pharmaceuticals, Inc. reported Stockholders Equity of $216.20 million for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $216.20M | -35.9% |
| 2024 | $337.19M | -22.9% |
| 2023 | $437.28M | +0.8% |
| 2022 | $433.80M | +19.0% |
| 2021 | $364.48M | +9.3% |
| 2020 | $333.38M | +554.9% |
| 2019 | -$73.28M | -326.8% |
| 2018 | $32.31M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $252.87M | -28.6% | -7.9% |
| June 30, 2025 | $274.50M | -28.3% | -7.1% |
| March 31, 2025 | $295.38M | -35.6% | -12.4% |
| December 31, 2024 | $337.19M | -22.9% | -4.8% |
| September 30, 2024 | $354.33M | -26.5% | -7.4% |
| June 30, 2024 | $382.58M | -26.9% | -16.6% |
| March 31, 2024 | $458.77M | +19.0% | +4.9% |
| December 31, 2023 | $437.28M | +0.8% | -9.2% |
- Zentalis Pharmaceuticals, Inc. showed a decrease of -35.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Zentalis Pharmaceuticals, Inc.’s stockholders equity has grown by 569.2% (from $32.31 million to $216.20 million).
- The most recent figure is from Zentalis Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: